Alivus Life Sciences Schedules Investor Meeting for September 2025

Alivus Life Sciences Limited has scheduled a meeting with investors and analysts for September 2, 2025. This meeting complies with Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, aimed at fostering transparency and communication with stakeholders.

The session will be conducted virtually and will take the format of one-on-one interactions, facilitated by Sowilo Investment Managers. This approach allows for personalized discussions, catering to the specific interests of each investor and analyst involved.

While the meeting is set for September 2, it is important to note that both the schedule and the mode of the meeting may change due to unforeseen circumstances related to the participants, including the company itself. Rudalf Corriea, Company Secretary and Compliance Officer of Alivus Life Sciences Limited, has formally signed the notification regarding this meeting.

Investors and analysts interested in attending should monitor updates through official channels, particularly under the scrip code 543322 on BSE Ltd. and the scrip name ALIVUS on the National Stock Exchange of India Ltd.. This proactive communication reflects Alivus Life Sciences’ commitment to maintaining strong relationships with its stakeholders while adhering to regulatory requirements.

As the date approaches, further details are expected to be released, ensuring that all interested parties are well-informed about the meeting’s logistics and content.